Inhibition of Corneal Neovascularization by Topical and Subconjunctival Tigecycline
Figure 2
The percentage of corneal neovascularization by groups. Subconjunctivally tigecycline-treated eyes (group 3) showed significantly less corneal neovascularization than other groups.